Company news
Fate Therapeutics, Inc. news in 2021
Fate Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
December 12, 2021
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
December 12, 2021
Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting
December 7, 2021
Fate Therapeutics Announces Abstract Highlighting FT538 and FT573 Programs Selected for Presentation at SITC 2021 Annual Meeting Press Conference
November 8, 2021
Fate Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Operational Progress
November 3, 2021
Fate Therapeutics Announces Eight Presentations at the 2021 ASH Annual Meeting
November 3, 2021
Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
October 24, 2021
Fate Therapeutics Announces Presentations at the Society for Immunotherapy of Cancer 2021 Annual Meeting
September 30, 2021
Fate Therapeutics Announces Publication of FT538 Preclinical Data Demonstrating Enhanced Serial Killing and Functional Persistence without Cytokine Support
September 14, 2021
Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma
August 18, 2021
Fate Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
August 3, 2021
Fate Therapeutics Appoints Yuan Xu to its Board of Directors
August 3, 2021
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy
August 1, 2021
Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma
July 15, 2021
Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results
July 14, 2021
Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer
June 14, 2021
Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with Rituximab for B-cell Lymphoma at 2021 ASCO Annual Meeting
June 3, 2021
Fate Therapeutics Announces Encouraging Interim Phase 1 Data for iPSC-derived NK Cell Programs in Relapsed / Refractory Acute Myeloid Leukemia
May 12, 2021
Fate Therapeutics Reports First Quarter 2021 Financial Results and Highlights Operational Progress
May 4, 2021
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2021 Financial Results
April 28, 2021
Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting
April 26, 2021
Fate Therapeutics Announces Retirement of Chief Scientific Officer after 12 Years of Service
March 24, 2021
Fate Therapeutics Reports Fourth Quarter 2020 Financial Results and Highlights Operational Progress
February 23, 2021
Fate Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 21, 2021
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2020 Financial Results
February 18, 2021
Fate Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants, and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 7, 2021
Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
January 4, 2021
Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock
January 3, 2021
Calls in 2021
Decks in 2021
- Investor Presentation (January 2021)
Investor deck · 53 slides · January 2021